Atrial Fibrillation Clinical Trials

Birmingham : 1160.128.1046 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Birmingham : University of Alabama at Birmingham

Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study

Birmingham : 1160.129.32261 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Birmingham : University of Alabama, Birmingham

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Birmingham : University of Alabama, Birmingham

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

View More »

Gulf Shores : 1160.129.32023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Huntsville : 1160.128.1045 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Mobile : 1160.128.1003 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Mobile :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Pell City : 1160.129.32172 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Scottsboro : 1160.129.32054 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tuscaloosa : 1160.129.32174 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Jonesboro : 1160.129.32150 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chandler : 1160.128.1093 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Chandler : 1160.129.32254 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Glendale : 1160.129.32284 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hot Springs : 1160.129.32156 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Havasu City : 1160.129.32151 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Phoenix : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Phoenix : Clinical Research Advantage, Inc.

CARTO® 3 System and Real Time Intracardiac Ultrasound

Phoenix : AZ Heart Rhythm Center

CARTO® 3 System and Real Time Intracardiac Ultrasound

Phoenix : Arizona Heart Rhythm Research Center

Continued Access to PREVAIL (CAP2)

Phoenix : 1160.129.32159 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Phoenix : 1160.129.32250 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fort Smith : 1160.129.32266 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hot Springs : 1160.128.1067 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hot Springs : 1160.129.32140 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Little Rock : Arkansas Cardiology, PA

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Little Rock : 1160.129.32014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Little Rock : 1160.129.32009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Santa Ana : Coastal Multi-Specialty Research

Cardiovascular outcomes study to evaluate the potential to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event & type II diabetes mellitus.

Santa Ana : Coastal Multi-Specialty Research

Patients who have Type II diabetes & coronary artery disease, post angiogram or heart attack. This is a phase 3b study. Currently open for enrollment.

Santa Ana : Coastal Multi-Specialty Research

RESCUE cardiovascular clinical trial

View More »

Beverly Hills : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

El Cajon :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Encinitas : 1160.129.32035 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fountain Valley : 1160.129.32126 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fresno : 1160.129.32019 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fresno :

REVEAL AF: Incidence of AF in High Risk Patients

Fullerton : St. Jude Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Hawaiian Gardens : 1160.129.32305 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Healdsburg :

REVEAL AF: Incidence of AF in High Risk Patients

Hollywood : 1160.129.32230 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

La Jolla : 1160.129.32225 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

La Mesa : 1160.129.32216 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Los Alamitos : 1160.129.32039 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Los Angeles : Ronald Reagan UCLA Medical Center

ABLATE AF Registry Trial

Los Angeles : Good Samaritan Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Merced : 1160.129.32043 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

National City :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Newport Beach : 1160.128.1094 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Orange : Orange County Heart Institute and Research Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Palo Alto : Stanford Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Rancho Mirage : 1160.129.32170 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sacramento : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Sacramento :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Sacramento : Regional Cardiology Associates, Mercy General Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

San Diego : 1160.128.1042 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

San Diego : University of California San Diego Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Diego : 1160.129.32017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

San Francisco : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

San Francisco : University of California at San Francisco Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Francisco : UCSF

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

San Jose : Good Samaritan Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Santa Ana : 1160.129.32051 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Santa Barbara : Santa Barbara Cottage Hospital

CARTO® 3 System and Real Time Intracardiac Ultrasound

Santa Monica : Pacific Heart Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Santa Rosa : 1160.129.32330 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Stanford : Stanford University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Stanford : Stanford University Medical Center

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study ( Staged DEEP)

Stanford : Stanford University School of Medicine

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Stanford : Stanford Univeristy Medical Center

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Stockton : 1160.129.32102 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tarzana : Heart Rythm Specialists of Southern California

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Temecula : 1160.129.32167 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32249 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32205 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ventura : 1160.129.32196 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Visalia : 1160.129.32104 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Aurora : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Aurora : The Medical Center of Aurora

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Aurora : Aurora Denver Cardiology Associates

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Aurora : 1160.129.32031 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Colorado Springs : 1160.128.1005 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

View More »

Colorado Springs : Penrose Saint Francis Health Services

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Colorado Springs : 1160.129.32204 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Colorado Springs : 1160.129.32021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Denver : 1160.128.1023 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Denver : Colorado Heart and Vascular

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Waterbury : Chase Medical Research, LLC

A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa® With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa® 150 mg b.i.d. or 75 mg b.i.d. for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation (NVAF)

View More »

Bridgeport : 1160.128.1066 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Bridgeport : 1160.128.1016 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Bridgeport : 1160.129.32233 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bridgeport : 1160.129.32193 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bridgeport : 1160.129.32268 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Guilford : 1160.128.1018 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hartford : Hartford Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Milford : 1160.129.32008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Norwalk : 1160.128.1050 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Norwalk : 1160.129.32074 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Norwalk : 1160.129.32303 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Shelton : 1160.129.32152 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Stamford :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Waterbury : 1160.128.1057 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Newark : 1160.129.32066 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Washington : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Washington : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Washington : George Washington University Medical Faculty Associates

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Washington : 1160.129.32202 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Washington : 1160.129.32314 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Daytona Beach : Cardiology Research Associates

Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

View More »

Atlantis : JFK Medical Center

CARTO® 3 System and Real Time Intracardiac Ultrasound

Atlantis : JFK Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Aventura : 1160.129.32270 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bradenton :

REVEAL AF: Incidence of AF in High Risk Patients

Brandon : 1160.128.1032 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Brandon : 1160.129.32292 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Brandon : 1160.129.32144 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Clearwater : 1160.129.32119 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Coral Gables : 1160.129.32304 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Coral Springs : 1160.128.1021 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Coral Springs :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Daytona Beach : 1160.128.1027 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Daytona Beach : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Daytona Beach : Daytona Heart Group

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Delray Beach : 1160.129.32048 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Doral : 1160.129.32291 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fort Lauderdale : Broward General Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Gainesville : University of Florida - Shands Hospital

ABLATE AF Registry Trial

Gainesville : 1160.129.32132 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Gainesville :

REVEAL AF: Incidence of AF in High Risk Patients

Gainesville : University of Florida

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Hialeah : 1160.129.32310 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Hollywood :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hollywood : 1160.129.32318 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hollywood : 1160.129.32128 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Jacksonville : 1160.128.1062 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Jacksonville : 1160.128.1019 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Jacksonville : Diagnostic Cardiology Associates PA

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Jacksonville : Saint Vincent's Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Jacksonville : Mayo Clinic Jacksonville

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Jupiter : 1160.129.32090 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kissimmee : Osceola Regional Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Lakeland : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Lakeland : 1160.129.32079 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Largo : 1160.128.1054 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Miami : 1160.128.1097 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Miami : 1160.129.32094 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32296 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32124 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32076 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32276 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32212 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miami : 1160.129.32222 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miramar Beach : 1160.129.32125 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New Smyrna Beach : 1160.129.32005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oakland Park : 1160.129.32147 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Orlando : 1160.128.1087 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Orlando : Florida Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Orlando : 1160.129.32182 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Orlando : Florida Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Panama City : 1160.129.32281 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pembroke Pines : 1160.129.32063 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pensacola : 1160.128.1058 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Pensacola : 1160.129.32239 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pismo Beach : 1160.129.32136 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Port Charlotte : 1160.128.1007 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Port Charlotte : 1160.129.32208 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Rockledge : 1160.128.1060 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Rockledge : 1160.129.32259 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Sarasota : 1160.129.32248 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : 1160.129.32313 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sarasota : 1160.129.32006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Seminole : 1160.129.32020 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Petersburg : Northside Hospital and Heart Institute

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Petersburg : 1160.129.32116 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Petersburg : 1160.129.32213 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Petersburg : 1160.129.32057 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tallahassee : Tallahassee Resesarch Institute, Inc.

CARTO® 3 System and Real Time Intracardiac Ultrasound

Tallahassee : Tallahassee Memorial Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tallahassee :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tallahassee : 1160.129.32064 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tampa : Pepin Heart Hospital

ABLATE AF Registry Trial

Tampa : Florida Heart Rhythm-University of South Florida College of Medicine

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tampa : 1160.129.32277 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tampa : Florida Heart Rhythm Institute

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Venice : Venice Regional Medical Center

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Wellington : 1160.129.32037 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : 1160.129.32302 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : 1160.129.32253 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : 1160.129.32178 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Atlanta : Emory University Hospital Midtown

Management of New-Onset Postoperative Atrial Fibrillation

Atlanta : Emory University Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

View More »

Atlanta : Piedmont Heart Institute

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Augusta : Georgia Health Sciences University

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Columbus : 1160.128.1096 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Cumming : 1160.129.32185 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Decatur : 1160.129.32083 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Macon : Georgia Arrhythmia Consultants & Research Institute

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Roswell : 1160.128.1068 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Coeur d'Alene : 1160.128.1076 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Coeur d'Alene : 1160.129.32096 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Arlington Heights : 1160.129.32283 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Aurora :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Barrington : Alexian Brothers Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Belleville : 1160.129.32071 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

View More »

Chicago : Rush University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Chicago : 1160.129.32044 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32293 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32298 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32103 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : 1160.129.32065 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chicago : University of Chicago Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Chicago : Northwestern University

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring

Chicago : Northwestern Memorial Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Elk Grove Village : Alexian Brothers Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Evanston : NorthShore University Health System

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hinsdale : 1160.129.32117 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Joliet : Provena Saint Joseph Medical Center

CARTO® 3 System and Real Time Intracardiac Ultrasound

Maywood :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Maywood : Loyola University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Maywood : Loyola University Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Maywood : Loyola University Chicago

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Melrose Park : 1160.128.1073 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Melrose Park : 1160.129.32003 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Morton : 1160.129.32133 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Park Ridge : Advocate Lutheran General Hospital Updated

A Study Comparing a High Flow of Saline Catheter to a Low Flow of Saline Catheter During RadioFrequency Ablation Study in Patients With Atrial Fibrillation

Rock Island : 1160.129.32275 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Rockford :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Springfield : St. John's Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Springfield : Prairie Heart Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Winfield : 1160.128.1048 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Bloomington : 1160.129.32106 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bloomington :

REVEAL AF: Incidence of AF in High Risk Patients

Brownsburg : 1160.129.32001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fort Wayne : Lutheran Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Hammond : 1160.129.32046 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Indianapolis : 1160.128.1029 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Indianapolis : Heart Center of Indiana

ABLATE AF Registry Trial

Indianapolis : St. Francis Heart Center

ABLATE AF Registry Trial

Indianapolis : Saint Vincent Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Indianapolis : 1160.129.32245 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

La Porte : 1160.129.32320 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Muncie : Medical Consultants, P.C.

Ibutilide Administration During Pulmonary Vein Ablation

Newburgh : 1160.129.32210 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

South Bend : 1160.129.32327 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

South Bend :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Ames : 1160.129.32042 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Iowa City : University of Iowa Hospital & Clinics

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Waterloo : 1160.129.32055 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

West Des Moines : Mercy Medical Center-Iowa Heart Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

West Des Moines : 1160.129.32089 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kansas City : The Univ. of Kansas Hospital

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Kansas City : University of Kansas Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Kansas City : The University of Kansas Medical Center

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Kansas City : University of Kansas Hospitals

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Overland Park : 1160.128.1079 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

View More »

Overland Park : 1160.129.32029 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Overland Park :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Bowling Green : 1160.129.32010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Elizabethtown : 1160.129.32025 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lexington : Central Baptist Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Lexington : Central Baptist Hospital

Continued Access to PREVAIL (CAP2)

Lexington : Central Baptist Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

View More »

Lexington : Central Baptist Hospital

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Louisville : Baptist Hospital East

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Mount Sterling : 1160.129.32188 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Owensboro : 1160.129.32059 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Alexandria : 1160.129.32176 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Baton Rouge : 1160.128.1008 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Baton Rouge : 1160.129.32286 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bossier City : 1160.129.32201 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hammond : 1160.129.32045 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Kenner : 1160.129.32271 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lafayette : 1160.129.32056 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32214 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32169 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lake Charles : 1160.129.32235 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New Orleans : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

New Orleans : 1160.129.32274 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Slidell : 1160.129.32164 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Auburn : 1160.128.1025 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Biddeford : 1160.129.32122 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Annapolis : 1160.129.32226 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : Johns Hopkins Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Baltimore : 1160.129.32228 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : 1160.129.32207 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Baltimore : University of Maryland

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

View More »

Baltimore : Johns Hopkins Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Baltimore : Johns Hopkins

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Baltimore : Johns Hopkins Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Glen Burnie : 1160.129.32247 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salisbury : 1160.128.1012 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Salisbury : 1160.129.32148 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salisbury : 1160.129.32155 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Silver Spring : Washington Adventist Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Takoma Park : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Takoma Park : 1160.129.32256 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Takoma Park : Washington Adventist Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Towson : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Towson : 1160.129.32229 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ayer : 1160.129.32203 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Boston : Massachusetts General Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Boston : Brigham and Womens Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Boston : Massachusetts General Hospital

Deviating the Esophagus in Atrial Fibrillation Ablation

Boston : Beth Israel Deaconess Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

View More »

Boston : Brigham and Women's Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Boston : Massachusetts General Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Boston : Beth Israel Deaconess Medical Center

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring

Boston : Brigham and Women's Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Boston : Massachusetts General Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Boston : Brigham and Women's Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Boston : Massachusetts General Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Fall River : 1160.129.32013 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Natick : 1160.129.32294 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Newton : 1160.129.32289 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Worcester : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Alpena : 1160.129.32036 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ann Arbor : University of Michigan Cardiovascular Center

Effects of Fish Oil on Post Ablation Arrhythmias

Bay City : 1160.129.32234 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Detroit : 1160.129.32135 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Flint : 1160.129.32047 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Grand Blanc : 1160.129.32264 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Grand Blanc : 1160.129.32168 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Grand Rapids : Spectrum Health

ABLATE AF Registry Trial

Grand Rapids : Spectrum Health

AMPLATZER Cardiac Plug Clinical Trial

Grand Rapids : Spectrum Health

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Lansing : Thoracic & Cardiovascular Healthcare Foundation

ABLATE AF Registry Trial

Lansing : 1160.129.32052 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Marquette : 1160.129.32142 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Mount Clemens : 1160.129.32232 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Muskegon : 1160.128.1017 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Niles : 1160.129.32053 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Novi : 1160.129.32282 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Rochester : 1160.129.32134 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Rochester Hills : 1160.128.1015 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Royal Oak : Beaumont Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Royal Oak : William Beaumont Hospital

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Saginaw : 1160.129.32231 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Saginaw : 1160.129.32075 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Southfield : Providence Hospital

AMPLATZER Cardiac Plug Clinical Trial

Traverse City : Munson Medical Center

ABLATE AF Registry Trial

Troy : William Beaumont Hospital

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Ypsilanti : Saint Joseph Mercy Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Chaska : 1160.129.32024 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Minneapolis : Minneapolis V.A. Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Minneapolis : 1160.129.32280 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Minneapolis : Park Nicollet Institute

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Minneapolis : Abbott Northwestern Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

View More »

Rochester : Mayo Clinic Rochester

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Rochester : Mayo Clinic Rochester/St. Mary's Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Rochester : Mayo Clinic

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Saint Paul : HealthEast St. Joseph's Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

St. Cloud : 1160.129.32190 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis Park :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

St. Louis Park : Park Nicollet Methodist Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

St. Paul : HealthEast St. Joseph's Hospital

AMPLATZER Cardiac Plug Clinical Trial

St. Paul : 1160.129.32307 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Jackson :

REVEAL AF: Incidence of AF in High Risk Patients

Tupelo : 1160.128.1004 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Columbia : 1160.128.1014 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kansas City : 1160.128.1047 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kansas City : Mid-America Heart Institute

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

St. Louis : Washington University/Barnes Jewish Hospital

ABLATE AF Registry Trial

St. Louis : Saint John's Mercy Heart Health Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

St. Louis : 1160.129.32101 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : 1160.129.32297 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : 1160.129.32184 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. Louis : 1160.129.32143 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Great Falls : 1160.128.1069 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kalispell : 1160.128.1011 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kalispell : 1160.129.32165 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Missoula : The International Heart Institute of Montana

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Lincoln : Nebraska Heart Hospital

ABLATE AF Registry Trial

Lincoln : BryanLGH Heart Institute

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Lincoln : Bryan LGH

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Omaha : 1160.128.1059 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Omaha : 1160.129.32321 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Omaha :

REVEAL AF: Incidence of AF in High Risk Patients

Papillion : 1160.129.32199 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Henderson : Cardiovascular Consultants of Nevada

Safety of Amiodarone and Ranolazine Together in Patients With Angina

Las Vegas : Cardiovascular Consultants of Nevada

Safety of Amiodarone and Ranolazine Together in Patients With Angina

Reno : 1160.129.32180 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bridgewater :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Bridgewater : 1160.129.32154 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Camden : Cooper University Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Elmer : 1160.128.1039 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Englewood : 1160.129.32181 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Flemington : 1160.128.1035 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hackensack : Hackensack University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Haddon Heights : 1160.129.32179 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hammonton : 1160.129.32198 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Linden : 1160.129.32030 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Neptune : 1160.129.32049 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New Brunswick : Robert Wood Johnson University Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Ocean : 1160.129.32242 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Paterson : 1160.129.32255 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ridgewood :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Ridgewood : Valley Health System

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation

Ridgewood : The Valley Hospital

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Ridgewood : 1160.129.32221 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Ridgewood :

REVEAL AF: Incidence of AF in High Risk Patients

Ridgewood : The Valley Hospital

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Somerset : 1160.129.32099 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

South Plainfield : 1160.129.32007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toms River :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Voorhees : 1160.129.32069 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

West Orange : 1160.129.32269 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Albuquerque : 1160.128.1036 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Albuquerque :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Albany : Albany Associates in Cardiology

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Albany : 1160.129.32332 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bronx : Montefiore Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bronx : 1160.129.32173 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bronxville : 1160.129.32084 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Brooklyn : 1160.129.32246 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Buffalo :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Flushing :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Hawthorne : 1160.128.1063 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Huntington : 1160.129.32195 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Johnson City : 1160.129.32278 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Mineola : 1160.128.1078 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Mineola : 1160.129.32038 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New York : 1160.128.1083 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New York : Columbia University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

New York : New York University Langone Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

New York : New York University Updated

Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation

New York : Mount Sinai Medical Center

Continued Access to PREVAIL (CAP2)

New York : Icahn School of Medicine at Mount Sinai

Deviating the Esophagus in Atrial Fibrillation Ablation

New York : 1160.129.32110 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

New York : St. Luke's Roosevelt Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

New York : Mt. Sinai Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

New York : Mount Sinai Medical Center

TOCCASTAR - TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation

Poughkeepsie : 1160.128.1001 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Rochester : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Rochester : University of Rochester Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Roslyn : St. Francis Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Staten Island : Staten Island University Hosptial

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

Stony Brook : Stony Brook University Hospital and Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Stony Brook : Stony Brook Univeristy Medical Center

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Syracuse : 1160.129.32139 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Syracuse : 1160.129.32015 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Utica : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Utica : Mohawk Valley Heart Institute / St. Elizabeth Medical Center

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Westfield : 1160.129.32263 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Williamsville : 1160.129.32209 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Williamsville : 1160.129.32016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Asheboro : 1160.129.32194 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Asheville : 1160.128.1022 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Burlington : 1160.129.32265 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chapel Hill : University of North Carolina at Chapel Hill

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Charlotte : The Sanger Clinic, PA

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Charlotte : Carolinas Medical Center/Sanger Heart & Vascular

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Durham : Duke University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Durham : Duke University Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Durham : Duke University

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Durham : Duke University Medical Center

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Durham : Duke University Health System

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Gastonia : 1160.128.1052 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Greensboro : 1160.129.32022 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hickory : 1160.129.32070 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

High Point : 1160.129.32033 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Jacksonville : 1160.129.32114 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kannapolis : 1160.129.32251 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lenoir : 1160.129.32072 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Pinehurst : 1160.129.32073 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Raleigh : 1160.129.32162 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sanford :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Statesville : 1160.128.1071 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Wilson : 1160.129.32215 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Winston-Salem : Wake Forest University Health Sciences

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Fargo : 1160.129.32118 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Minot : 1160.129.32220 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Cincinnati : Good Samaritan Hospital

ABLATE AF Registry Trial

Cincinnati : MediSync Clinical Research

CARTO® 3 System and Real Time Intracardiac Ultrasound

Cincinnati : University of Cincinnati Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cincinnati : Medisync

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cincinnati : Bethesda North Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

View More »

Cincinnati : Bethesda North Hospital l TriHealth Hatton Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Cleveland : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Cleveland : Cleveland Clinic

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Cleveland : 1160.129.32273 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Cleveland : Cleveland Clinic Foundation

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Cleveland : Cleveland Clinic

Siemens 3-D C-Arm CT of the Heart Chambers

Cleveland : Cleveland Clinic Foundation

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Columbus : The Ohio State University

AMPLATZER Cardiac Plug Clinical Trial

Columbus : Ohio State University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Columbus : Ohio State University Medical Center Updated

Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation

Columbus : The Ohio State University

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Columbus : Ohio State University

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Columbus : Ohio State University

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Fairfield : 1160.129.32257 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fairview Park : 1160.129.32061 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Gallipolis : 1160.128.1091 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Gallipolis : 1160.129.32011 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hudson : 1160.129.32060 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kettering : 1160.129.32183 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Marion : 1160.129.32316 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Marion : 1160.129.32158 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miamisburg : 1160.129.32012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Miamisburg :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Springfield : 1160.129.32244 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toledo : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Toledo : University of Toledo

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Toledo :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Toledo : 1160.129.32285 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Youngstown : 1160.129.32032 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Zanesville : Genesis Healthcare Systems

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Oklahoma City : Oklahoma Heart Hospital

ABLATE AF Registry Trial

Oklahoma City : 1160.129.32258 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oklahoma City : University of Oklahoma

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Oklahoma City : OU Medical Center

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

Oklahoma City : University of Oklahoma

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

View More »

Tulsa : Oklahoma Heart Institute

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Tulsa : Oklahoma Heart Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Bend : 1160.128.1053 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Hillsboro : 1160.128.1033 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Portland : Oregon Health and Science University

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Portland : Providence Saint Vincent Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Portland : 1160.129.32163 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Altoona : 1160.128.1037 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Camp Hill : 1160.128.1034 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Camp Hill : 1160.129.32236 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Camp Hill : Capital Cardiovascular Associates

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Carnegie : 1160.129.32086 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Chambersburg : 1160.129.32206 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Danville : Geisinger Wyoming Valley Medical Center

CARTO® 3 System and Real Time Intracardiac Ultrasound

Danville : Geisinger Wyoming Valley Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Doylestown : Doylestown Cardiology Associates/Central Bucks

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Doylestown :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Doylestown : 1160.129.32157 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Doylestown : Doylestown Hospital

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Doylestown : Doylestown Cardiology Associates

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Erie : 1160.128.1072 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Harleysville : 1160.129.32113 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Harrisburg : Pinnacle Health

ABLATE AF Registry Trial

Harrisburg : Pinnacle Health

ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal AF

Hershey : Penn State University Cardiovascular Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Jersey Shore : 1160.129.32127 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lancaster : Lancaster Heart & Stroke Foundation

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Lancaster : Lancaster Heart & Stroke

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Langhorne : 1160.128.1010 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Langhorne : St. Mary Medical Center

CARTO® 3 System and Real Time Intracardiac Ultrasound

Lansdale : 1160.129.32153 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Penndel : 1160.129.32115 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Philadelphia : Hospital of the University of Pennsylvania

CARTO® 3 System and Real Time Intracardiac Ultrasound

Philadelphia : University of Pennsylvania Health System

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Philadelphia : Drexel University College of Medicine

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Philadelphia : 1160.129.32323 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Philadelphia : Hospital of the University of Pennsylvania

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Philadelphia : Albert Einstein Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Philadelphia : Hospital of the University of Pennsylvania

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Philadelphia : University of Pennslyvania

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Pittsburgh : 1160.128.1056 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Pittsburgh : UPMC Presbyterian Shadyside

Atrial Fibrillation Recurrence After Cryoballoon Ablation

Pittsburgh : UPMC Passavant

Atrial Fibrillation Recurrence After Cryoballoon Ablation

Pittsburgh : V.A. Pittsburgh Healthcare System

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Pittsburgh : University of Pittsburgh Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Sayre : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Uniontown : 1160.128.1065 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Warminster : 1160.129.32109 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Wynnewood : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Wynnewood : Lankenau Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Yardley : 1160.129.32137 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

York : York Hospital

AMPLATZER Cardiac Plug Clinical Trial

Pawtucket : 1160.129.32224 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Wakefield :

REVEAL AF: Incidence of AF in High Risk Patients

Anderson : 1160.129.32243 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Anderson : 1160.129.32160 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Anderson :

REVEAL AF: Incidence of AF in High Risk Patients

Beaufort : 1160.129.32002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Charleston : 1160.128.1043 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

View More »

Charleston : Medical University of South Carolina

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Charleston : Medical University South Carolina

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Columbia : Sisters of Charity, Providence Hospital

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Columbia : 1160.129.32050 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Greenville : Greenville Memorial Hospital

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Myrtle Beach : 1160.129.32108 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Rapid City : 1160.128.1040 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Rapid City :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rapid City : 1160.129.32267 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chattanooga : 1160.129.32217 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Chattanooga :

REVEAL AF: Incidence of AF in High Risk Patients

Johnson City : 1160.129.32272 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kingsport : Wellmont CVA Heart Institute

CARTO® 3 System and Real Time Intracardiac Ultrasound

Knoxville : 1160.129.32287 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Knoxville : 1160.129.32080 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Knoxville : 1160.129.32082 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Memphis : Baptist Memorial Hospital

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

Nashville : Vanderbilt University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Nashville : St. Thomas Research Institute

Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

Nashville : Vanderbilt Heart Institute

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study ( Staged DEEP)

Nashville : 1160.129.32186 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Nashville : Saint Thomas Research Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

New Tazewell : 1160.129.32223 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : DM Clinical Research

Atrial Fibrillation - Houston, TX

View More »

Austin : 1160.128.1098 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Austin :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Austin : Texas Cardiac Arrhythmia

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Austin : Texas Cardiac Arrhythmia Research Foundation Updated

Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation

Austin : 1160.129.32145 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Austin : Austin Heart PA

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Austin : Texas Cardiac Arrhythmia Research - St. David's

nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

Austin : Texas Cardiac Arrhythmia Research Foundation

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Austin : Texas Cardiac Arrhythmia Foundation

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Austin : Texas Cardiac Arrhythmia Research Foundation (TCARF)

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Austin : Texas Cardiac Arrhythmia Institute

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Beaumont : 1160.129.32095 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Dallas : Baylor Heart and Vascular Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Dallas : 1160.129.32322 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Dallas : 1160.129.32290 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Dallas : 1160.129.32252 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Dallas : University of Texas Southwestern Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Dallas : Baylor Heart and Vascular

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Dallas : Baylor Research Institute

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Fort Worth : Baylor All Saints Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Fort Worth : 1160.129.32097 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fort Worth : 1160.129.32300 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fort Worth : Baylor All Saints Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Fort Worth : Plaza Medical Center

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Grapevine : 1160.129.32105 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Houston : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Houston : University of Texas Health Science Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Houston : 1160.129.32100 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32111 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32092 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32301 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32123 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32295 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : 1160.129.32027 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Houston : Methodist Hospital

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Houston : Saint Luke's Episcopal Hospital - Texas Medical Center

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Houston : Houston Methodist

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Humble : 1160.129.32219 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Katy : 1160.129.32171 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Killeen : 1160.128.1006 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Kingwood : 1160.129.32211 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Lubbock : 1160.129.32260 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

McKinney : 1160.128.1061 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New Braunfels : 1160.128.1090 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

New Braunfels : 1160.129.32189 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

North Richland Hills : 1160.129.32177 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Odessa : 1160.129.32197 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Odessa :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Plano : The Heart Hospital Baylor

AMPLATZER Cardiac Plug Clinical Trial

Plano : The Heart Hospital Baylor Plano

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Plano : Baylor Research Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

San Antonio : 1160.128.1082 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

San Antonio : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

San Antonio : South Texas Cardiovascular Consultants

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

San Antonio : 1160.129.32238 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

San Antonio : 1160.129.32187 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sealy : 1160.129.32288 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Seguin : 1160.128.1089 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Seguin : 1160.129.32191 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sugar Land : 1160.129.32040 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sugar Land : 1160.129.32068 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Temple : Scott & White Memorial Hospital

CARTO® 3 System and Real Time Intracardiac Ultrasound

Temple : Scott and White Memorial Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

The Woodlands : 1160.129.32319 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

The Woodlands :

REVEAL AF: Incidence of AF in High Risk Patients

Tomball : 1160.129.32091 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tomball :

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Tyler :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Waco : 1160.129.32093 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Whitney : 1160.129.32175 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Bountiful : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Layton :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Murray : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Murray : Intermountain Medical Center

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Salt Lake City : St. Mark's

ABLATE AF Registry Trial

View More »

Salt Lake City : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Salt Lake City : Intermountain Medical Center-LDS Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Salt Lake City : 1160.129.32034 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salt Lake City : 1160.129.32121 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Burke : 1160.129.32166 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Charlottesville : University of Virginia Health System

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Charlottesville : University of Virginia Health System

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Charlottesville : Univeristy of Virginia

Use of the Hansen Medical System in Patients With Atrial Fibrillation

Chesapeake : 1160.129.32004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Danville : 1160.128.1077 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Danville : 1160.129.32067 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Fairfax : Inova Fairfax Hospital

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Falls Church : 1160.128.1064 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Falls Church : Fairfax Hospital, Department of Cardiovascular and Thoracic Surgery

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

Falls Church : 1160.129.32146 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Manassas : 1160.129.32328 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Manassas : 1160.129.32200 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Midlothian : 1160.129.32279 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Norfolk : 1160.128.1099 Boehringer Ingelheim Investigational Site

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Norfolk : Sentara Norfolk General Hospital

ABLATE AF Registry Trial

Norfolk : Sentara Norfolk General Hospital

CARTO® 3 System and Real Time Intracardiac Ultrasound

Norfolk : Sentara Norfolk General Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Norfolk : Sentara Norfolk Hospital

Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study ( Staged DEEP)

Norfolk : Sentara Cardiovascular Research Institute

Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Richmond : University of Virginia Commonwealth/Medical College of Virginia

ABLATE AF Registry Trial

Richmond : Otsuka Investigational Site

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Richmond : Virginia Commonwealth University Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Richmond : Virginia Commonwealth University

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Richmond : Virginia Commonwealth University

THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS

Burien : 1160.129.32062 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Port Orchard : 1160.129.32227 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Seattle : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Seattle : Swedish Medical Center

ABLATE AF Registry Trial

Seattle : Swedish Medical Center - Providence Campus

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Seattle : University of Washington Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Seattle : 1160.129.32241 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tacoma : Cardiac Study Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Huntington : 1160.129.32028 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Green Bay : Bellin Memorial Hospital Inc.

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

La Crosse : 1160.129.32308 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : Medical College of Wisconsin

CARTO® 3 System and Real Time Intracardiac Ultrasound

Milwaukee : Aurora Saint Lukes Medical Center

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Milwaukee : Aurora St. Luke's Medical Center

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

View More »

Milwaukee : 1160.129.32088 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32325 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32058 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : 1160.129.32041 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Milwaukee : St. Luke's Medical Center

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Wausau : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Wausau : Aspirus Wausau Hospital

ABLATE AF Registry Trial

Wausau :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Buenos Aires : 1160.129.21008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Buenos Aires : 1160.129.21009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Capital Federal : 1160.129.21007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Corrientes : 1160.129.21006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

San Jose Gaymallen : 1160.129.21002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Adelaide : Royal Adelaide Hospital

Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)

Adelaide : Royal Adelaide Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Adelaide : Royal Adelaide Hospital

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Herston : Royal Brisbane and Women's Hospital

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Parkville : Royal Melbourne Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

View More »

Parkville : Royal Adelaide Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Westmead : Westmead Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Westworthville : Westmead Hospital

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Graz : Marianne Brodmann

Global Anticoagulant Registry in the Field

Graz : LKH/Uniklinikum - Klinische Abteilung für Kardiologie

Graz Study on the Risk of Atrial Fibrillation

Innsbruck : 1160.136.34002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Linz : A. ö. Krankenhaus der Elisabethinen Linz

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Linz : 1160.136.34001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

View More »

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Neupölla : 1160.136.34005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Oberwart : 1160.136.34008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Vienna : MSD Osterreich GmbH

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Wien : Allgemeines Krankenhaus der Stadt Wien

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Antwerpen : AZ Middelheim

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Antwerpen : ZNA Middelheim

PRECISION GOLD Post Market Study in Europe of Pulmonary Vein Ablation Catheter (PVAC GOLD)

Antwerpen : ZNA Campus Middelheim Lindendreef 1

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Bonheiden : Imelda Ziekenhuis

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Brugge : A.Z. St Jan AV

Atrial Fibrillation Progression Trial

View More »

Bruxelles - Brussel :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Ghent : Drug Research Unit Ghent

A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.

Gilly :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hasselt :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Leuven :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Liege :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

MOL :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Belo Horizonte : 1160.129.22012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Belo Horizonte : 1160.129.22011 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Blumenau : 1160.129.22029 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Brasilia : 1160.129.22004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Curitiba : 1160.129.22016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Passo Fundo : 1160.129.22021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Porto Alegre : 1160.129.22005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Porto Alegre : 1160.129.22026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Porto Alegre : 1160.129.22006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salvador : 1160.129.22002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Salvador : 1160.129.22023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Santo Andre : 1160.129.22007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sao Jose do Rio Preto : 1160.129.22001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sao Paulo : Hospital Sao Paulo

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Sao Paulo : 1160.129.22018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sao Paulo : 1160.129.22003 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sao Paulo : 1160.129.22008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Tatui : 1160.129.22032 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Votuporanga : 1160.129.22025 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Burgas : 1160.136.36004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Kazanlak : 1160.136.36002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Plovdiv : 1160.136.36008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Rousse : 1160.136.36005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sevlievo : 1160.136.36001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

View More »

Sliven : 1160.136.36013 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sofia : 1160.136.36014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sofia : 1160.136.36012 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Sofia : 1160.136.36011 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Stara Zagora : 1160.136.36009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Yambol : 1160.136.36006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Antigonish : 1160.129.06010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Calgary : University of Calgary

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Calgary : 1160.129.06018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Calgary : University of Calgary, Foothills Hospital

Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins

Cambridge : 1160.129.06023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

View More »

Chicoutimi : 1160.129.06024 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Coquitlam : 1160.129.06005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Downsview : 1160.129.06003 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Edmonton :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Edmonton : 1160.129.06004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Edmonton : Royal Alexandra Hospital

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Grimsby : 1160.129.06020 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Halifax : 1160.129.06025 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hamilton :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hamilton : 1160.129.06016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Hamilton : 1160.129.06032 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kelowna : 1160.129.06027 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Kingston : Kingston General Hospital

Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study

Levis : 1160.129.06014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

London : London Health Sciences Center

DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation

London : University of Western Ontario

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

MIssissauga : 1160.129.06028 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Montreal :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Montreal : 1160.129.06009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Montreal : Montreal Heart Institute (Institut de Cardiologie de Montreal)

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Montreal : Hôpital du Sacre Coeur de Montreal

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Montreal : Montreal Heart Institute

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Newmarket : Southlake Regional Health Centre

Efficiency Study Evaluating the Use of the PVAC Catheter Technology for Performing Ablation in Patients With Atrial Fibrillation

Newmarket : Southlake Regional Health Center

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Oakville : 1160.129.06017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Oshawa : 1160.129.06001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Quebec : Institut Universitaire de Cardiologie et de Pneumologie de Québec

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Québec : 1160.129.06006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Richmond : 1160.129.06034 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Sainte-Foy : 1160.129.06022 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Saskatoon : 1160.129.06002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St. John's : 1160.129.06007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

St-Jean-sur-Richel : 1160.129.06030 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toronto :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Toronto : 1160.129.06026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06029 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Toronto : 1160.129.06031 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Vancouver : Saint Pauls Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Vancouver : St. Paul's Hospital

Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases

Victoria : 1160.129.06021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Victoria : Victoria Cardiac Arrhythmia Trials Inc

Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Beijing : Beijing Anzhen Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Beijing : Fuwai Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Guangzhou : Guangdong Provincial People's Hospital

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Nanjing : First Affiliated Hospital of Nanjing Medical University

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Xi'an :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Bogotá : 1160.129.24006 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Cartagena de Indias : 1160.129.24007 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Manizales : 1160.129.24008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Quindio : 1160.129.24005 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program - Second and Third Phases

Prague : Na Homolce Hospital, Cardiology

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Prague 4 : IKEM

Evaluation of a New Cardiac Pacemaker

Prague 5 : Na Homolce Hospital

Evaluation of a New Cardiac Pacemaker

Glostrup : Merck Sharp & Dohme

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Hellerup :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Herning :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hvidovre : Department of Cardiology, Copenhagen University Hospital, Hvidovre

Atrial Fibrillation (AF) and Physical Exercise

København NV :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

View More »

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Viborg :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Valencia : 1160.136.03021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Tallin : 1160.136.38001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Tallinn : 1160.136.38002 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lappeenranta :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Oulu :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Pori :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tampere :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Turku :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

View More »

Vaasa :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Abbeville : CHG

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Antony : Hopital Privé

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Arbois : 1160.136.13059 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Arras :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Auxerre : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

View More »

Avignon : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Avignon : 1160.136.13060 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bagnols sur Ceze : 1160.136.13035 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bersée : 1160.136.13015 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Besancon : 1160.136.13039 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Beziers : 1160.136.13036 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Beziers : 1160.136.13040 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bordeaux : Clinique de Bordeaux Cauderan

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Bordeaux : 1160.136.13004 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Broglie : 1160.136.13045 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bruay la Buissière : 1160.136.13054 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Caen : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Cannes : 1160.136.13014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Castres : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Chateauroux : 1160.136.13046 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Cherbourg : 1160.136.13025 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Clamart : HIA Percy

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Clermont Ferrand : 1160.136.13017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Dinan : CH René Pleven

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Dole : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Dunkerque : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Evecquemont : 1160.136.13063 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Evreux : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Grenoble : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Grenoble : CHU Grenoble

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Le Chesnay : CMC Parly II

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Le Coudray : 1160.136.13058 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Le Havre : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Levallois Perret : 1160.136.13010 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Libourne : 1160.136.13008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Libourne : 1160.136.13044 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lille : CHU Lille

European Carto XP Registry for Validating Specialized CFAE Software

Lille Cedex :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Limoges : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Limoges : 1160.136.13078 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lomme : CH Saint Philibert

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Many locations :

Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication

Many Locations :

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Marseille : Hôpital La Timone

Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.

Marseille : Clinique de la Casamance

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : CHU La Timone

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : Clinique Bouchard

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Marseille : Hopital Saint Joseph

European Carto XP Registry for Validating Specialized CFAE Software

Marseille : 1160.136.13075 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Marseille cedex 5 : 1160.136.13047 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Martigues : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Metz : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Mondelange : 1160.136.13019 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montargis : 1160.136.13056 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montauban : 1160.136.13013 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montauban : 1160.136.13053 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montfermeil : 1160.136.13048 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montfermeil : 1160.136.13001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Montpellier :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Montpellier : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Montpellier : CHU Arnaud de Villeneuve

European Carto XP Registry for Validating Specialized CFAE Software

Montpellier : 1160.136.13072 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Mulhouse : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Nancy : CHU Hôpital de Brabois

European Carto XP Registry for Validating Specialized CFAE Software

Nantes : CHU Nantes

European Carto XP Registry for Validating Specialized CFAE Software

Neuilly : Ambroise Paré

European Carto XP Registry for Validating Specialized CFAE Software

Neuilly sur Seine : Clinique Ambroise Paré

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Neuilly sur Seine : 1160.136.13064 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Nimes : Hopital Les Franciscaines

European Carto XP Registry for Validating Specialized CFAE Software

Nimes : 1160.136.13018 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Orléans : 1160.136.13065 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Paris cedex 13 :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Pessac : Hopital Cardiologique du Haut Leveque

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Quincy-sous-Sénart : Hopital Privé Claude Galien

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : Polyclinique Saint Laurent

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rennes : CHU de Rennes

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Rennes Cedex : 1160.136.13066 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Rouen : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Rouen : University Hospital of Rouen

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Saint Etienne : CHU

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Saint Laurent du Var : Institut Arnalt Tzanck

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Saint-etienne : CHU de Saint-Etienne

Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter

Saint-Yrieix-la-Perche : 1160.136.13026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Schiltigheim : CMCO

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Strasbourg : 1160.136.13067 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Thionville : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Toulon : CH Toulon

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Toulouse : Clinique Pasteur

Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation

Toulouse : La Clinique Pasteur, 45 Avenue de Lombez

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Toulouse : 1160.136.13023 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

TOULOUSE cedex :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Tourcoing : 1160.136.13003 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Tours : 1160.136.13043 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Valence : 1160.136.13050 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Valenciennes : CH

Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation

Vandoeuvre Les Nancy :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Vandoeuvre-les-nancy :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Vihiers : 1160.136.13021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Wattrelos : 1160.136.13038 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Aachen : Boehringer Ingelheim Investigational Site 585 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 600 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 584 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aachen : Boehringer Ingelheim Investigational Site 601 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aalen : Boehringer Ingelheim Investigational Site 145 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

View More »

Aalen : Boehringer Ingelheim Investigational Site 147 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aarbergen : Boehringer Ingelheim Investigational Site 442 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 775 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 796 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 801 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahaus : Boehringer Ingelheim Investigational Site 779 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ahrensburg : Boehringer Ingelheim Investigational Site 1077 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aichtal : Boehringer Ingelheim Investigational Site 166 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aichtal : Boehringer Ingelheim Investigational Site 157 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albersloh : Boehringer Ingelheim Investigational Site 842 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 76 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 72 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt : Boehringer Ingelheim Investigational Site 94 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Albstadt-Ebingen : Boehringer Ingelheim Investigational Site 91 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alfeld : Boehringer Ingelheim Investigational Site 895 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alfter : Boehringer Ingelheim Investigational Site 624 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Allersberg : Boehringer Ingelheim Investigational Site 197 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alpenrod : Boehringer Ingelheim Investigational Site 443 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenburg : Boehringer Ingelheim Investigational Site 1165 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenburg : Boehringer Ingelheim Investigational Site 1187 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenburg : Boehringer Ingelheim Investigational Site 1166 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenholz : Boehringer Ingelheim Investigational Site 1052 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenholz : Boehringer Ingelheim Investigational Site 1084 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altenstadt : Boehringer Ingelheim Investigational Site 507 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Altlussheim : Boehringer Ingelheim Investigational Site 135 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 214 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 211 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Alzenau : Boehringer Ingelheim Investigational Site 212 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 338 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 327 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Amberg : Boehringer Ingelheim Investigational Site 324 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Anderbeck : Boehringer Ingelheim Investigational Site 1282 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Apolda : Boehringer Ingelheim Investigational Site 1146 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Apolda : Boehringer Ingelheim Investigational Site 1154 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arenshausen : Boehringer Ingelheim Investigational Site 1138 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnsberg : Boehringer Ingelheim Investigational Site 765 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnstadt : Boehringer Ingelheim Investigational Site 1145 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Arnstadt : Boehringer Ingelheim Investigational Site 1143 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Attendorn : Boehringer Ingelheim Investigational Site 737 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Attenkirchen : Boehringer Ingelheim Investigational Site 275 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Au am Rhein : Boehringer Ingelheim Investigational Site 11 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Aue : Boehringer Ingelheim Investigational Site 1181 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 282 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 294 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 305 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 285 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 281 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Augsburg : Boehringer Ingelheim Investigational Site 304 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Bederkesa : Boehringer Ingelheim Investigational Site 1008 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Bentheim : Boehringer Ingelheim Investigational Site 969 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Berka : Zentraklinik Bad Berka

PRECISION GOLD Post Market Study in Europe of Pulmonary Vein Ablation Catheter (PVAC GOLD)

Bad Breisig : Boehringer Ingelheim Investigational Site 448 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Driburg : Boehringer Ingelheim Investigational Site 750 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Elster : Boehringer Ingelheim Investigational Site 1186 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 427 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 415 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ems : Boehringer Ingelheim Investigational Site 414 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Friedrichshall : Boehringer Ingelheim Investigational Site 127 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 495 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 497 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Homburg v.d.H. : Boehringer Ingelheim Investigational Site 494 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Klosterlausnitz : Boehringer Ingelheim Investigational Site 1169 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Kreuznach : Boehringer Ingelheim Investigational Site 418 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Krozingen : Herz-Zentrum

A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy

Bad Krozingen :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Bad Krozingen : Universitäts-Herzzentrum Freiburg - Bad Krozingen

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Bad Krozingen : Herz-Zentrum Bad Krozingen

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Bad Krozingen : Herzzentrum Bad Krozingen, Elektrophysiologie

Ventricular Pacing Site Selection (V-PASS)

Bad Langensalza : Boehringer Ingelheim Investigational Site 1125 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 875 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 874 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Lauterberg : Boehringer Ingelheim Investigational Site 878 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Muenstereifel : Boehringer Ingelheim Investigational Site 636 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Bad Nauheim : Kerckhoff-Klinik gGmbH

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Bad Nauheim : Kerckhoff Klinik

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Bad Nauheim : Boehringer Ingelheim Investigational Site 424 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Boehringer Ingelheim Investigational Site 492 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Boehringer Ingelheim Investigational Site 425 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nauheim : Boehringer Ingelheim Investigational Site 493 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nenndorf : Boehringer Ingelheim Investigational Site 1458 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Nenndorf : Boehringer Ingelheim Investigational Site 929 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neuenahr : Boehringer Ingelheim Investigational Site 420 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neustadt : Boehringer Ingelheim Investigational Site 210 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Neustadt/Saale : Herz- und Gefäß-Klinik

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Bad Neustadt/Saale : Klinik für Kardiologie II mit interventioneller Elektrophysiologie

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Bad Oeynhausen : Herz- und Diabeteszentrum Nordrhein-Westfalen

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Bad Oeynhausen : Herz -und Diabeteszentrum

DEtermining Accuracy and TrEnding CharacTerization of AF

Bad Oeynhausen :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Bad Oeynhausen : IKFE HDZ GbmH

Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study

Bad Pyrmont : Boehringer Ingelheim Investigational Site 926 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Reichenhall : Boehringer Ingelheim Investigational Site 235 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Reichenhall : Boehringer Ingelheim Investigational Site 234 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sachsa : Boehringer Ingelheim Investigational Site 876 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sachsa : Boehringer Ingelheim Investigational Site 877 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Saeckingen : Boehringer Ingelheim Investigational Site 18 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzuflen : Boehringer Ingelheim Investigational Site 832 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzuflen : Boehringer Ingelheim Investigational Site 816 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzungen : Boehringer Ingelheim Investigational Site 1128 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Salzungen : Boehringer Ingelheim Investigational Site 1140 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schussenried : Boehringer Ingelheim Investigational Site 84 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schussenried : Boehringer Ingelheim Investigational Site 83 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Schwartau : Boehringer Ingelheim Investigational Site 1048 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Soden am Taunus : Boehringer Ingelheim Investigational Site 496 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Sulza : Boehringer Ingelheim Investigational Site 1150 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Tennstedt : Boehringer Ingelheim Investigational Site 1476 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Tennstedt : Boehringer Ingelheim Investigational Site 1475 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Ueberkingen : Boehringer Ingelheim Investigational Site 96 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Waldsee : Boehringer Ingelheim Investigational Site 74 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wiesee : Boehringer Ingelheim Investigational Site 241 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wildbad : Boehringer Ingelheim Investigational Site 39 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bad Wildbad : Boehringer Ingelheim Investigational Site 64 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Badel : Boehringer Ingelheim Investigational Site 1291 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baden hausen : Boehringer Ingelheim Investigational Site 902 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baden-Baden : Boehringer Ingelheim Investigational Site 3 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baindt : Boehringer Ingelheim Investigational Site 79 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baindt : Boehringer Ingelheim Investigational Site 80 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bamberg : Boehringer Ingelheim Investigational Site 1398 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bamberg : Boehringer Ingelheim Investigational Site 1404 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Barchfeld : Boehringer Ingelheim Investigational Site 1153 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bargteheide : Boehringer Ingelheim Investigational Site 1076 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Barssel/Harkebruegge : Boehringer Ingelheim Investigational Site 1422 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Barssel/Harkebruegge : Boehringer Ingelheim Investigational Site 965 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baruth : Boehringer Ingelheim Investigational Site 1349 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bassum : Boehringer Ingelheim Investigational Site 1479 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bassum : Boehringer Ingelheim Investigational Site 912 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baumholder : Boehringer Ingelheim Investigational Site 417 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Baunatal : Boehringer Ingelheim Investigational Site 531 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bautzen : Boehringer Ingelheim Investigational Site 1352 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bayreuth : Boehringer Ingelheim Investigational Site 352 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bayreuth : Boehringer Ingelheim Investigational Site 1485 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bechhofen : Boehringer Ingelheim Investigational Site 387 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beckum : Boehringer Ingelheim Investigational Site 826 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beckum : Boehringer Ingelheim Investigational Site 825 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beilrode : Boehringer Ingelheim Investigational Site 1372 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bellngries : Boehringer Ingelheim Investigational Site 205 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bendorf : Boehringer Ingelheim Investigational Site 436 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bensheim : Boehringer Ingelheim Investigational Site 481 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bensheim : Boehringer Ingelheim Investigational Site 455 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berg. Gladbach : Boehringer Ingelheim Investigational Site 850 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bergen : Boehringer Ingelheim Investigational Site 1116 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bergkamen-Ruenthe : Boehringer Ingelheim Investigational Site 761 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Universitätsmedizin Berlin - Charité Campus Virchow-Klinikum (CVK)

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Berlin : Charité Campus Virchow-Klinikum

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Berlin : Franz-Volhard-Klinik, Universitätsklinikum Charité

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Berlin : Charité Campus Mitte

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Berlin : Vivantes-Klinikum am Urban

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Berlin : Boehringer Ingelheim Investigational Site 1323 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1237 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1238 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1293 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1232 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1199 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1195 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1245 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1242 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1322 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1222 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1197 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1189 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1241 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1300 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1220 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1227 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1301 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1225 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1228 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1446 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1200 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1067 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1247 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1226 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1203 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 367 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1254 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1302 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1196 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1221 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1252 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1306 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1239 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1448 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1234 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1303 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1244 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1198 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1304 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1298 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1223 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1236 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1246 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1235 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1305 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1190 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1447 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1231 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin : Boehringer Ingelheim Investigational Site 1324 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Berlin :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Berlin : 1160.136.02021 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02039 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02001 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02036 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02020 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin : 1160.136.02016 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Berlin-Lankwitz : Boehringer Ingelheim Investigational Site 1194 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bernau : Boehringer Ingelheim Investigational Site 1224 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bernau : Boehringer Ingelheim Investigational Site 1449 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bernsdorf : Boehringer Ingelheim Investigational Site 1348 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beselich-Obertiefenbach : Boehringer Ingelheim Investigational Site 430 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Beselich-Obertiefenbach : Boehringer Ingelheim Investigational Site 444 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bettingen : Boehringer Ingelheim Investigational Site 571 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biberach : Boehringer Ingelheim Investigational Site 73 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biblis : Boehringer Ingelheim Investigational Site 476 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biedenkopf : Boehringer Ingelheim Investigational Site 545 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Biedenkopf : Boehringer Ingelheim Investigational Site 525 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bielefeld : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Bielefeld : Städtische Kliniken Bielefeld

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Bielefeld : Boehringer Ingelheim Investigational Site 843 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bielefeld : Boehringer Ingelheim Investigational Site 818 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bingen : Boehringer Ingelheim Investigational Site 90 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bischofferode : Boehringer Ingelheim Investigational Site 1136 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bischofsheim : Boehringer Ingelheim Investigational Site 469 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bismark : Boehringer Ingelheim Investigational Site 1292 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bitterfeld : Boehringer Ingelheim Investigational Site 1286 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bitterfeld : Boehringer Ingelheim Investigational Site 1287 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Blaubeuren : Boehringer Ingelheim Investigational Site 88 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bleicherode : Boehringer Ingelheim Investigational Site 1473 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Blomberg : Boehringer Ingelheim Investigational Site 838 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Blumberg : Boehringer Ingelheim Investigational Site 53 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bobritzsch : Boehringer Ingelheim Investigational Site 1336 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bocholt : St. Agnes Hospital Bocholt

PRECISION GOLD Post Market Study in Europe of Pulmonary Vein Ablation Catheter (PVAC GOLD)

Bochum : Boehringer Ingelheim Investigational Site 720 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 726 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 722 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 728 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 724 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 727 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 718 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bochum : Boehringer Ingelheim Investigational Site 729 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bodenkirchen : Boehringer Ingelheim Investigational Site 316 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boeblingen : Boehringer Ingelheim Investigational Site 48 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boeblingen : Boehringer Ingelheim Investigational Site 45 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boeblingen : Boehringer Ingelheim Investigational Site 1466 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boehlen : Boehringer Ingelheim Investigational Site 1369 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonn : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Bonn : St. Marien Hospital

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Bonn : Boehringer Ingelheim Investigational Site 638 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonndorf : Boehringer Ingelheim Investigational Site 38 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bonndorf : Boehringer Ingelheim Investigational Site 51 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Boostedt : Boehringer Ingelheim Investigational Site 1061 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bordesholm : Boehringer Ingelheim Investigational Site 1085 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borgholzhausen : Boehringer Ingelheim Investigational Site 841 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borken : Boehringer Ingelheim Investigational Site 788 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Borna : Boehringer Ingelheim Investigational Site 1386 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bottrop : Boehringer Ingelheim Investigational Site 795 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bottrop : Boehringer Ingelheim Investigational Site 783 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bovenden-Reyershausen : Boehringer Ingelheim Investigational Site 903 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braeunlingen : Boehringer Ingelheim Investigational Site 50 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Brake : Boehringer Ingelheim Investigational Site 949 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Brake : Boehringer Ingelheim Investigational Site 962 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bramsche : Boehringer Ingelheim Investigational Site 977 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunsbedra : Boehringer Ingelheim Investigational Site 1368 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 884 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 890 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 882 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Braunschweig : Boehringer Ingelheim Investigational Site 881 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Breitenguessbach : Boehringer Ingelheim Investigational Site 1406 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Zentralkrankenhaus Links der Weser, Siebels & Langes Partnerschaft

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Bremen : Boehringer Ingelheim Investigational Site 1000 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1004 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1003 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1002 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 990 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 999 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 1001 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : Boehringer Ingelheim Investigational Site 998 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremen : 1160.136.02042 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Bremerhaven : Boehringer Ingelheim Investigational Site 983 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 1011 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 985 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremerhaven : Boehringer Ingelheim Investigational Site 982 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bremervoerde : Boehringer Ingelheim Investigational Site 987 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bretten : Boehringer Ingelheim Investigational Site 132 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Brilon : Boehringer Ingelheim Investigational Site 753 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bruchweiler-Baerenbach : Boehringer Ingelheim Investigational Site 403 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchbach : Boehringer Ingelheim Investigational Site 314 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchbach : Boehringer Ingelheim Investigational Site 315 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchholz : Boehringer Ingelheim Investigational Site 1015 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buchholz : Boehringer Ingelheim Investigational Site 988 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buckow : Boehringer Ingelheim Investigational Site 1251 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buechen : Boehringer Ingelheim Investigational Site 1069 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buechen : Boehringer Ingelheim Investigational Site 1408 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buechen : Boehringer Ingelheim Investigational Site 1427 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buechen : Boehringer Ingelheim Investigational Site 1070 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bueckeburg : Boehringer Ingelheim Investigational Site 909 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Buende : Boehringer Ingelheim Investigational Site 820 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Bueren : Boehringer Ingelheim Investigational Site 773 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burg (Spreewald) : Boehringer Ingelheim Investigational Site 1212 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burgdorf : Boehringer Ingelheim Investigational Site 925 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Burgneudorf : Boehringer Ingelheim Investigational Site 1347 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Butzbach : Boehringer Ingelheim Investigational Site 519 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop Rauxel : Boehringer Ingelheim Investigational Site 747 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 769 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 757 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Castrop-Rauxel : Boehringer Ingelheim Investigational Site 759 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1158 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1177 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1176 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1161 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1175 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1160 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1178 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1179 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1172 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Chemnitz : Boehringer Ingelheim Investigational Site 1159 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coburg : Klinikum Coburg

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Coburg : Klinikum Coburg

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Coburg : Boehringer Ingelheim Investigational Site 381 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coburg : Klinikum Coburg

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Cochem : Boehringer Ingelheim Investigational Site 447 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Coswig : Boehringer Ingelheim Investigational Site 1270 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Cottbus : Boehringer Ingelheim Investigational Site 1210 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Crinitz : Boehringer Ingelheim Investigational Site 1214 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dachau : Boehringer Ingelheim Investigational Site 279 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dachau : Boehringer Ingelheim Investigational Site 276 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dargun : Boehringer Ingelheim Investigational Site 1113 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Darmstadt : Boehringer Ingelheim Investigational Site 454 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Darmstadt : Boehringer Ingelheim Investigational Site 456 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Darmstadt : Boehringer Ingelheim Investigational Site 480 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dautphetal : Boehringer Ingelheim Investigational Site 554 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Deggendorf : Boehringer Ingelheim Investigational Site 331 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Delitzsch : Boehringer Ingelheim Investigational Site 1378 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Delitzsch : Boehringer Ingelheim Investigational Site 1487 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Demmin : Boehringer Ingelheim Investigational Site 1115 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dessau-Rosslau : Boehringer Ingelheim Investigational Site 1272 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dessau-Roßlau : 1160.136.02017 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Detmold : Boehringer Ingelheim Investigational Site 835 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Detmold : 1160.136.02041 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Dieburg : Boehringer Ingelheim Investigational Site 491 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dieburg : Boehringer Ingelheim Investigational Site 490 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Diepenau : Boehringer Ingelheim Investigational Site 938 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Diessen : Boehringer Ingelheim Investigational Site 223 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dietzhoelztal : Boehringer Ingelheim Investigational Site 547 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dillingen/Saar : Boehringer Ingelheim Investigational Site 560 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 199 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 209 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinkelsbuehl : Boehringer Ingelheim Investigational Site 185 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinklage : Boehringer Ingelheim Investigational Site 967 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinslaken : Boehringer Ingelheim Investigational Site 675 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dinslaken : 1160.136.02014 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Dinslaken-Averbruch : Boehringer Ingelheim Investigational Site 709 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Doberan : Boehringer Ingelheim Investigational Site 1111 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Doerfles-Esbach : Boehringer Ingelheim Investigational Site 377 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dogern : Boehringer Ingelheim Investigational Site 19 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dormagen : Boehringer Ingelheim Investigational Site 654 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Dortmund : Boehringer Ingelheim Investigational Site 770 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 599 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 596 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 744 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 746 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 745 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 749 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 748 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 743 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : Boehringer Ingelheim Investigational Site 756 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dortmund : 1160.136.02033 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Dreieich : Boehringer Ingelheim Investigational Site 514 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Praxisklinik Herz and Gefaesse

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Dresden : Boehringer Ingelheim Investigational Site 1342 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1357 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1346 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1343 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1355 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1345 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1326 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1344 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1327 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Boehringer Ingelheim Investigational Site 1356 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dresden : Praxisklinik - Herz- und Gefässe

Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)

Dresden :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Dresden : Zentrum fuer klinische Pruefungen in der Facharztzentrum Dresden-Neustadt GbR

PRECISION GOLD Post Market Study in Europe of Pulmonary Vein Ablation Catheter (PVAC GOLD)

Driedorf : Boehringer Ingelheim Investigational Site 549 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Drochtersen : Boehringer Ingelheim Investigational Site 1025 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Drochtersen : Boehringer Ingelheim Investigational Site 1024 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Dudenhofen : Boehringer Ingelheim Investigational Site 399 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 861 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 666 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 645 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 652 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 648 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 650 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 649 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 667 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 668 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 859 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf : Boehringer Ingelheim Investigational Site 848 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duesseldorf (Benrath) : Boehringer Ingelheim Investigational Site 860 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 689 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 686 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 691 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 679 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 681 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 680 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg : Boehringer Ingelheim Investigational Site 688 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Duisburg (Walsum) : Boehringer Ingelheim Investigational Site 690 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Durach : Boehringer Ingelheim Investigational Site 219 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Durmersheim : Boehringer Ingelheim Investigational Site 31 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Düsseldorf : Evangelisches Krankenhaus Düsseldorf

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Ebeleben : Boehringer Ingelheim Investigational Site 1134 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ebergoetzen : Boehringer Ingelheim Investigational Site 905 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ebersburg-Schmalnau : Boehringer Ingelheim Investigational Site 541 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eckernfoerde : Boehringer Ingelheim Investigational Site 1035 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eckernfoerde : Boehringer Ingelheim Investigational Site 1042 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Edewecht : Boehringer Ingelheim Investigational Site 953 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Edling : Boehringer Ingelheim Investigational Site 257 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Efringen-Kirchen : Boehringer Ingelheim Investigational Site 17 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehingen : Boehringer Ingelheim Investigational Site 82 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehrenkirchen : Boehringer Ingelheim Investigational Site 24 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ehringshausen : Boehringer Ingelheim Investigational Site 499 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eichstaett : Boehringer Ingelheim Investigational Site 187 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eilenburg : Boehringer Ingelheim Investigational Site 1392 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Einbeck : Boehringer Ingelheim Investigational Site 904 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ellwangen/Jagst : Boehringer Ingelheim Investigational Site 143 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elsterwerda : Boehringer Ingelheim Investigational Site 1193 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elsterwerda : Boehringer Ingelheim Investigational Site 1218 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elsterwerda : Boehringer Ingelheim Investigational Site 1191 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Elz : Boehringer Ingelheim Investigational Site 441 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Engelskirchen-Ruenderoth : Boehringer Ingelheim Investigational Site 631 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ennigerloh-Ostenfelde : Boehringer Ingelheim Investigational Site 823 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eppelborn : Boehringer Ingelheim Investigational Site 575 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eppingen : Boehringer Ingelheim Investigational Site 130 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erfde : Boehringer Ingelheim Investigational Site 1058 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erftstadt : Boehringer Ingelheim Investigational Site 642 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erftstadt : Boehringer Ingelheim Investigational Site 640 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erfurt : Boehringer Ingelheim Investigational Site 1133 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erkelenz : Boehringer Ingelheim Investigational Site 610 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Erlangen : Boehringer Ingelheim Investigational Site 181 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 198 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 177 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 207 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 180 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 176 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 179 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erlangen : Boehringer Ingelheim Investigational Site 206 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Erligheim : Boehringer Ingelheim Investigational Site 122 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschborn : Boehringer Ingelheim Investigational Site 498 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschwege : Boehringer Ingelheim Investigational Site 528 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eschweiler : Boehringer Ingelheim Investigational Site 583 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Espelkamp : Boehringer Ingelheim Investigational Site 840 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 696 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 699 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 687 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 695 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 702 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 676 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 693 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 694 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 677 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 700 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 697 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 698 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen : Boehringer Ingelheim Investigational Site 701 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Essen :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Esslingen : Boehringer Ingelheim Investigational Site 137 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ettlingen : Boehringer Ingelheim Investigational Site 33 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Euskirchen : Boehringer Ingelheim Investigational Site 639 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Eutin : Boehringer Ingelheim Investigational Site 1047 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Falkensee : Boehringer Ingelheim Investigational Site 1312 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fassberg : Boehringer Ingelheim Investigational Site 920 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Felsberg-Gensungen : Boehringer Ingelheim Investigational Site 534 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1055 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1034 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1033 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Flensburg : Boehringer Ingelheim Investigational Site 1036 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Floeha : Boehringer Ingelheim Investigational Site 1331 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Florstadt / Staden : Boehringer Ingelheim Investigational Site 511 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Forchheim : Boehringer Ingelheim Investigational Site 1400 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Forchheim : Boehringer Ingelheim Investigational Site 1399 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankenberg : Boehringer Ingelheim Investigational Site 546 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : CCB - Cardioaniologisches Centrum Bethanien

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Frankfurt : Boehringer Ingelheim Investigational Site 486 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : Boehringer Ingelheim Investigational Site 482 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt : Boehringer Ingelheim Investigational Site 488 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Frankfurt : Cardioangiologisches Centrum Bethanien - CCB

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Frankfurt (Oder) : Boehringer Ingelheim Investigational Site 1201 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt am Main : Boehringer Ingelheim Investigational Site 512 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/M. : Boehringer Ingelheim Investigational Site 485 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/M. : Boehringer Ingelheim Investigational Site 513 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frankfurt/Oder : Boehringer Ingelheim Investigational Site 1202 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frechen : Boehringer Ingelheim Investigational Site 595 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiberg : Boehringer Ingelheim Investigational Site 1341 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiberg : Boehringer Ingelheim Investigational Site 1330 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 1418 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 6 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 22 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 23 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 5 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg : Boehringer Ingelheim Investigational Site 1 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freiburg :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Freinsheim : Boehringer Ingelheim Investigational Site 406 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freising : Boehringer Ingelheim Investigational Site 272 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Freital : Boehringer Ingelheim Investigational Site 1338 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fremdingen : Boehringer Ingelheim Investigational Site 188 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Frensdorf : Boehringer Ingelheim Investigational Site 354 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Friedrichshafen : Boehringer Ingelheim Investigational Site 99 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fritzlar : Boehringer Ingelheim Investigational Site 1453 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fritzlar : Boehringer Ingelheim Investigational Site 521 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 768 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 754 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Froendenberg : Boehringer Ingelheim Investigational Site 767 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenfeldbruck : Boehringer Ingelheim Investigational Site 319 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenfeldbruck-Aich : Boehringer Ingelheim Investigational Site 317 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenwalde/Spree : Boehringer Ingelheim Investigational Site 1206 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerstenwalde/Spree : Boehringer Ingelheim Investigational Site 1207 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fuerth : Boehringer Ingelheim Investigational Site 351 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Fulda : Boehringer Ingelheim Investigational Site 530 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gangkofen : Boehringer Ingelheim Investigational Site 346 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garching : Boehringer Ingelheim Investigational Site 301 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gardelegen : Boehringer Ingelheim Investigational Site 1290 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garmisch-Partenkirchen : Boehringer Ingelheim Investigational Site 222 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Garmisch-Patenkirchen : Boehringer Ingelheim Investigational Site 232 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gedern-Wenings : Boehringer Ingelheim Investigational Site 518 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geeste : Boehringer Ingelheim Investigational Site 964 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geesthacht : Boehringer Ingelheim Investigational Site 1078 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geisenkirchen-Buer : Boehringer Ingelheim Investigational Site 782 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geislingen/Steige : Boehringer Ingelheim Investigational Site 89 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geislingen/Steige : Boehringer Ingelheim Investigational Site 77 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 806 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 807 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 805 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 802 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 787 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 785 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 804 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gelsenkirchen : Boehringer Ingelheim Investigational Site 781 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gensingen : Boehringer Ingelheim Investigational Site 464 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Genthin : Boehringer Ingelheim Investigational Site 1256 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Genthin : Boehringer Ingelheim Investigational Site 1255 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gera : Boehringer Ingelheim Investigational Site 1156 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Geretsried : Boehringer Ingelheim Investigational Site 246 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gerlingen : Boehringer Ingelheim Investigational Site 37 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Germersheim : Boehringer Ingelheim Investigational Site 392 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gersfeld : Boehringer Ingelheim Investigational Site 553 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gerstetten : Boehringer Ingelheim Investigational Site 87 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giengen : Boehringer Ingelheim Investigational Site 75 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giessen : Boehringer Ingelheim Investigational Site 1481 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giessen : Boehringer Ingelheim Investigational Site 1482 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giessen : Boehringer Ingelheim Investigational Site 522 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Giessen : Boehringer Ingelheim Investigational Site 523 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gifhorn : Boehringer Ingelheim Investigational Site 883 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gilching : Boehringer Ingelheim Investigational Site 230 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Glindow : Boehringer Ingelheim Investigational Site 1308 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gluecksburg : Boehringer Ingelheim Investigational Site 1060 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goerlitz : Boehringer Ingelheim Investigational Site 1334 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goerlitz : Boehringer Ingelheim Investigational Site 1333 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goettingen : Universitätsmedizin Göttingen (UMG), Kardiologie und Pneumologie

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion

Goettingen-Weende : Boehringer Ingelheim Investigational Site 907 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Goldberg : Boehringer Ingelheim Investigational Site 1107 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Göttingen : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Graefelfing : Boehringer Ingelheim Investigational Site 251 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Graefenhainichen : Boehringer Ingelheim Investigational Site 1373 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grafenrheinfeld : Boehringer Ingelheim Investigational Site 192 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Greifswald : Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Greifswald : Universitätsklinikum Greifswald Elektrophysiologie

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Grenzach-Wyhlen : Boehringer Ingelheim Investigational Site 1419 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Griesheim : Boehringer Ingelheim Investigational Site 475 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grimmen : Boehringer Ingelheim Investigational Site 1117 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Groeden : Boehringer Ingelheim Investigational Site 1410 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Groeden : Boehringer Ingelheim Investigational Site 1434 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grossefehn : Boehringer Ingelheim Investigational Site 959 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gross-Groenau : Boehringer Ingelheim Investigational Site 1050 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Grossrosseln : Boehringer Ingelheim Investigational Site 563 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gross-Zimmern : Boehringer Ingelheim Investigational Site 515 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gruenstadt : Boehringer Ingelheim Investigational Site 390 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guenzburg : Boehringer Ingelheim Investigational Site 283 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 833 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 828 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Guetersloh : Boehringer Ingelheim Investigational Site 829 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gummersbach : Boehringer Ingelheim Investigational Site 615 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Gundelfingen : Boehringer Ingelheim Investigational Site 16 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haan : Boehringer Ingelheim Investigational Site 856 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haan : Boehringer Ingelheim Investigational Site 845 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haar : Boehringer Ingelheim Investigational Site 255 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haar : Merck Sharp & Dohme GmbH

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Hachenburg : Boehringer Ingelheim Investigational Site 416 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hadamar : Boehringer Ingelheim Investigational Site 446 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 710 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 731 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 733 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 717 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 730 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 711 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hagen : Boehringer Ingelheim Investigational Site 734 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haibach : Boehringer Ingelheim Investigational Site 1430 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haibach : Boehringer Ingelheim Investigational Site 196 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halberstadt : Boehringer Ingelheim Investigational Site 1284 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halberstadt : Boehringer Ingelheim Investigational Site 1262 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haldensleben : Boehringer Ingelheim Investigational Site 1265 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hallbergmoos : Boehringer Ingelheim Investigational Site 273 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1289 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1266 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 809 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1271 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 824 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1268 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1267 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 808 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 810 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle : Boehringer Ingelheim Investigational Site 1273 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Halle (Saale) : Boehringer Ingelheim Investigational Site 1274 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hallstadt : Boehringer Ingelheim Investigational Site 1405 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Investigational Site

A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Hamburg : ASKLEPIOS KLINIK St. Georg

Alster Man and Machine: Comparison of Manual and Mechanical Remote Robotic Catheter Ablation for Drug-Refractory Atrial Fibrillation

Hamburg : Asklepios Klinik St. Georg

Alster-Lost-AF-Study

Hamburg : Universitäres Herzzentrum Hamburg GmbH / UKE

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Hamburg : Asklepios Klinik St. Georg

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Hamburg : University Hospital Eppendorf

CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study

Hamburg : Asklepios Klinik Barmbek

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Asklepios Klinik St. Georg

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Universitares Herrzentrum Hamburg

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Hamburg : Boehringer Ingelheim Investigational Site 1071 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1039 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1038 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1029 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1486 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1080 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1026 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1414 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1091 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 991 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1072 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1086 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1028 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 992 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1045 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1087 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1431 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1073 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1044 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1079 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1027 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1037 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 995 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1022 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1023 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 993 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1021 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1030 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1089 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 994 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 1415 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Boehringer Ingelheim Investigational Site 996 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg : Klinik St. Georg

European Carto XP Registry for Validating Specialized CFAE Software

Hamburg :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Hamburg : Asklepios Klinik St. Georg

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Hamburg : Universitätskrankenhaus Eppendorf

Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)

Hamburg-Bergstedt : Boehringer Ingelheim Investigational Site 1075 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamburg-Bergstedt : Boehringer Ingelheim Investigational Site 1409 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hameln : Boehringer Ingelheim Investigational Site 927 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamm : Boehringer Ingelheim Investigational Site 763 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hamm : Boehringer Ingelheim Investigational Site 742 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hammelburg : Boehringer Ingelheim Investigational Site 213 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau : Boehringer Ingelheim Investigational Site 510 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau am Main : Boehringer Ingelheim Investigational Site 506 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanau/M. : Boehringer Ingelheim Investigational Site 508 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 941 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 918 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hannover : Boehringer Ingelheim Investigational Site 921 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanstedt : Boehringer Ingelheim Investigational Site 1020 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hanstedt : Boehringer Ingelheim Investigational Site 989 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Harsewinkel : Boehringer Ingelheim Investigational Site 813 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Haseluenne : Boehringer Ingelheim Investigational Site 963 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hassloch : Boehringer Ingelheim Investigational Site 385 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hassloch : Boehringer Ingelheim Investigational Site 408 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hausham : Boehringer Ingelheim Investigational Site 226 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Havixbeck : Boehringer Ingelheim Investigational Site 790 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heddesheim : Boehringer Ingelheim Investigational Site 119 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Klinikum der Ruprecht-Karls-Universität Heidelberg

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Heidelberg : Boehringer Ingelheim Investigational Site 104 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 113 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 101 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 108 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Boehringer Ingelheim Investigational Site 109 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidelberg : Department of Cardiology, University of Heidelberg

Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter

Heidelberg (Handschuhsheim) : Boehringer Ingelheim Investigational Site 118 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heidenheim : Boehringer Ingelheim Investigational Site 68 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbad Heiligenstadt : Boehringer Ingelheim Investigational Site 1474 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 123 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 129 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 126 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 124 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilbronn : Boehringer Ingelheim Investigational Site 111 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heiligenstadt : Boehringer Ingelheim Investigational Site 1137 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heilstedt : Boehringer Ingelheim Investigational Site 1281 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heimstetten : Boehringer Ingelheim Investigational Site 292 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heinsberg : Boehringer Ingelheim Investigational Site 594 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heist : Boehringer Ingelheim Investigational Site 1066 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hellenthal : Boehringer Ingelheim Investigational Site 634 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Helmstedt : Boehringer Ingelheim Investigational Site 885 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Helmstedt : Boehringer Ingelheim Investigational Site 887 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 1006 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 1007 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hemmoor : Boehringer Ingelheim Investigational Site 1010 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennef : Boehringer Ingelheim Investigational Site 621 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennef : Boehringer Ingelheim Investigational Site 625 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hennickendorf : Boehringer Ingelheim Investigational Site 1250 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Henstedt-Ulzburg : Boehringer Ingelheim Investigational Site 384 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Henstedt-Ulzburg : Boehringer Ingelheim Investigational Site 361 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hensted-Ulzburg : Boehringer Ingelheim Investigational Site 1043 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herbsleben : Boehringer Ingelheim Investigational Site 1130 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herford : Boehringer Ingelheim Investigational Site 819 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herford : Boehringer Ingelheim Investigational Site 815 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herne : Boehringer Ingelheim Investigational Site 803 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herne : Boehringer Ingelheim Investigational Site 1429 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herrenberg : Boehringer Ingelheim Investigational Site 34 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herrenberg-Affstaett : Boehringer Ingelheim Investigational Site 56 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Herrnhut : Boehringer Ingelheim Investigational Site 1351 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heubach : Boehringer Ingelheim Investigational Site 150 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heusweiler : Boehringer Ingelheim Investigational Site 577 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Heusweiler : Boehringer Ingelheim Investigational Site 580 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hilden : Boehringer Ingelheim Investigational Site 844 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hildesheim : Boehringer Ingelheim Investigational Site 901 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hilpoltstein : Boehringer Ingelheim Investigational Site 203 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hirschaid : Boehringer Ingelheim Investigational Site 264 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hirschaid : Boehringer Ingelheim Investigational Site 1401 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hirschau : Boehringer Ingelheim Investigational Site 339 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hochheim am Main : Boehringer Ingelheim Investigational Site 451 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoechberg : Boehringer Ingelheim Investigational Site 173 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoechberg : Boehringer Ingelheim Investigational Site 174 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoetensleben : Boehringer Ingelheim Investigational Site 1285 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohen Neuendorf/OT Bergfelde : Boehringer Ingelheim Investigational Site 1229 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenau : Boehringer Ingelheim Investigational Site 347 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenhameln : Boehringer Ingelheim Investigational Site 896 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hohenleipisch : Boehringer Ingelheim Investigational Site 1215 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoisdorf : Boehringer Ingelheim Investigational Site 1074 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Holm : Boehringer Ingelheim Investigational Site 1040 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Horb : Boehringer Ingelheim Investigational Site 44 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hoyerswerda : Boehringer Ingelheim Investigational Site 1350 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hude/Wuesting : Boehringer Ingelheim Investigational Site 966 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hueckelhoven : Boehringer Ingelheim Investigational Site 613 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Huerth : Boehringer Ingelheim Investigational Site 623 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Hummeltal : Boehringer Ingelheim Investigational Site 376 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ibbenbueren-Dickenberg : Boehringer Ingelheim Investigational Site 794 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Idar-Oberstein : Boehringer Ingelheim Investigational Site 422 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingelheim : Boehringer Ingelheim Investigational Site 461 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingersheim : Boehringer Ingelheim Investigational Site 128 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Klinikum Ingolstadt GmbH

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Ingolstadt : Boehringer Ingelheim Investigational Site 201 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Boehringer Ingelheim Investigational Site 265 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Boehringer Ingelheim Investigational Site 183 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Boehringer Ingelheim Investigational Site 200 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ingolstadt : Klinikum Ingolstadt GmbH

DEtermining Accuracy and TrEnding CharacTerization of AF

Ingolstadt : 1160.136.02051 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Irsch/Saar : Boehringer Ingelheim Investigational Site 581 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Iserlohn : Boehringer Ingelheim Investigational Site 735 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ismaning : Boehringer Ingelheim Investigational Site 309 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Issum : Boehringer Ingelheim Investigational Site 664 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jahnsdorf/Erzgeb. : Boehringer Ingelheim Investigational Site 1174 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena :

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Jena : Boehringer Ingelheim Investigational Site 1155 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena : Boehringer Ingelheim Investigational Site 1167 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jena-Lobeda : Boehringer Ingelheim Investigational Site 1168 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Jettingen-Unterjettingen : Boehringer Ingelheim Investigational Site 59 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Johannesberg : Boehringer Ingelheim Investigational Site 193 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juebek : Boehringer Ingelheim Investigational Site 1057 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juechen : Boehringer Ingelheim Investigational Site 665 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Juenkerath : Boehringer Ingelheim Investigational Site 567 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaebschuetztal/OT Kroegis : Boehringer Ingelheim Investigational Site 1340 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kahl : Boehringer Ingelheim Investigational Site 191 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 395 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 405 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 394 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 402 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kaiserslautern : Boehringer Ingelheim Investigational Site 396 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kalkar : Boehringer Ingelheim Investigational Site 663 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamen : Boehringer Ingelheim Investigational Site 758 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamen : Boehringer Ingelheim Investigational Site 762 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kamp-Lintfort : Boehringer Ingelheim Investigational Site 707 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kappeln : Boehringer Ingelheim Investigational Site 1056 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Saint Vincentius-Kliniken

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Karlsruhe : Boehringer Ingelheim Investigational Site 2 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 13 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 14 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 15 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 1484 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Boehringer Ingelheim Investigational Site 1483 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Karlsruhe : Stadtisches Klinikum Karlsruhe

European Carto XP Registry for Validating Specialized CFAE Software

Karlsruhe (Durlach) : Boehringer Ingelheim Investigational Site 12 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 1451 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 1452 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 1450 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 527 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 526 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : Boehringer Ingelheim Investigational Site 529 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kassel : 1160.136.02022 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Kempen : Boehringer Ingelheim Investigational Site 658 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempen : 1160.136.02009 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Kempten : Boehringer Ingelheim Investigational Site 216 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempten : Boehringer Ingelheim Investigational Site 217 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kempten : Boehringer Ingelheim Investigational Site 215 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kenzingen : Boehringer Ingelheim Investigational Site 28 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiedrich : Boehringer Ingelheim Investigational Site 466 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiel : Boehringer Ingelheim Investigational Site 1032 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiel : Boehringer Ingelheim Investigational Site 1054 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kiel : Boehringer Ingelheim Investigational Site 1031 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kierspe : Boehringer Ingelheim Investigational Site 739 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchardt : Boehringer Ingelheim Investigational Site 133 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchardt : Boehringer Ingelheim Investigational Site 134 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchenlamitz : Boehringer Ingelheim Investigational Site 340 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchheilingen : Boehringer Ingelheim Investigational Site 1129 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchheimbolanden : Boehringer Ingelheim Investigational Site 407 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchheimbolanden : Boehringer Ingelheim Investigational Site 409 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchzarten : Boehringer Ingelheim Investigational Site 4 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kirchzarten : 1160.136.02030 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Kleinmachnow : Boehringer Ingelheim Investigational Site 1294 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kleinostheim : Boehringer Ingelheim Investigational Site 1495 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klettgau-Griessen : Boehringer Ingelheim Investigational Site 52 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klingenberg : Boehringer Ingelheim Investigational Site 190 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Klingenthal : Boehringer Ingelheim Investigational Site 1183 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 605 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 604 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 608 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 591 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 617 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 589 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 626 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 629 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 630 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 612 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 587 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 592 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 616 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 593 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 611 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 622 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 618 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln : Boehringer Ingelheim Investigational Site 588 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln (Bilderstoeckchen) : Boehringer Ingelheim Investigational Site 606 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln-Hoehenberg : Boehringer Ingelheim Investigational Site 632 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koeln-Junkersdorf : Boehringer Ingelheim Investigational Site 590 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koenigsbrueck : Boehringer Ingelheim Investigational Site 1328 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koenigsbrunn : Boehringer Ingelheim Investigational Site 312 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koethen : Boehringer Ingelheim Investigational Site 1288 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Koethen : Boehringer Ingelheim Investigational Site 1258 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Konstanz : Herz-Zentrum-Bodensee Konstanz

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Krefeld : Boehringer Ingelheim Investigational Site 662 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 647 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 659 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krefeld : Boehringer Ingelheim Investigational Site 651 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kreuztal : Boehringer Ingelheim Investigational Site 716 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronach : Boehringer Ingelheim Investigational Site 373 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronberg/Ts : Boehringer Ingelheim Investigational Site 502 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronberg/Ts. : Boehringer Ingelheim Investigational Site 503 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronshagen : Boehringer Ingelheim Investigational Site 1083 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kronshagen : Boehringer Ingelheim Investigational Site 1082 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Krumbach : Boehringer Ingelheim Investigational Site 303 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Kuenzing : Boehringer Ingelheim Investigational Site 330 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

L.-Echterdingen : Boehringer Ingelheim Investigational Site 35 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laaber : Boehringer Ingelheim Investigational Site 342 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laage : Boehringer Ingelheim Investigational Site 1097 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laatzen : Boehringer Ingelheim Investigational Site 943 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laboe : Boehringer Ingelheim Investigational Site 1049 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laehden : Boehringer Ingelheim Investigational Site 1421 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lahnau : Boehringer Ingelheim Investigational Site 505 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Laichingen : Boehringer Ingelheim Investigational Site 85 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lalendorf : Boehringer Ingelheim Investigational Site 1112 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 458 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 478 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lampertheim : Boehringer Ingelheim Investigational Site 362 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Landau : Boehringer Ingelheim Investigational Site 391 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Landesbergen : Boehringer Ingelheim Investigational Site 1480 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Landshut : Krankenhaus Landshut-Achdorf

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Landshut : Boehringer Ingelheim Investigational Site 300 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenau : Boehringer Ingelheim Investigational Site 86 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenfeld : Boehringer Ingelheim Investigational Site 857 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenhagen : Boehringer Ingelheim Investigational Site 940 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Langenlonsheim : Boehringer Ingelheim Investigational Site 440 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauf : Boehringer Ingelheim Investigational Site 358 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauscha : Boehringer Ingelheim Investigational Site 1142 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lauterbach : Boehringer Ingelheim Investigational Site 544 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lebus : Boehringer Ingelheim Investigational Site 1248 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leck : Boehringer Ingelheim Investigational Site 1053 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leer : Boehringer Ingelheim Investigational Site 954 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lehrte : Boehringer Ingelheim Investigational Site 922 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leiblfing : Boehringer Ingelheim Investigational Site 236 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leinfelden-Echterdingen : Boehringer Ingelheim Investigational Site 41 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipheim : Boehringer Ingelheim Investigational Site 307 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Herzzentrum Leipzig GmbH

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Leipzig : Herzzentrum Leipzig

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Leipzig : Boehringer Ingelheim Investigational Site 1367 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1389 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1488 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1377 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1424 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1375 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1381 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1370 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1382 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1376 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig : Boehringer Ingelheim Investigational Site 1374 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leipzig :

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Leipzig : Herzzentrum Leipzig GmbH

Ventricular Wall Motion Characterization

Lemwerder : Boehringer Ingelheim Investigational Site 961 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengede-Woltwiesche : Boehringer Ingelheim Investigational Site 897 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengerich : Boehringer Ingelheim Investigational Site 780 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lengerich : Boehringer Ingelheim Investigational Site 776 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 862 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 853 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : Boehringer Ingelheim Investigational Site 863 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Leverkusen : 1160.136.02026 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Lichtenfels : Boehringer Ingelheim Investigational Site 378 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lichtentanne : Boehringer Ingelheim Investigational Site 1170 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Liebenau : Boehringer Ingelheim Investigational Site 538 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lienen-Kattenvenne : Boehringer Ingelheim Investigational Site 778 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lienen-Kattenvenne : Boehringer Ingelheim Investigational Site 791 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lilienthal : Boehringer Ingelheim Investigational Site 984 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Limburgerhof : Boehringer Ingelheim Investigational Site 401 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Limburgerhof : Boehringer Ingelheim Investigational Site 397 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindhorst : Boehringer Ingelheim Investigational Site 917 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindhorst : Boehringer Ingelheim Investigational Site 923 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindlar : Boehringer Ingelheim Investigational Site 619 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lindlar : Boehringer Ingelheim Investigational Site 620 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Linnich : Boehringer Ingelheim Investigational Site 609 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Loerrach : Boehringer Ingelheim Investigational Site 7 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lohfelden : Boehringer Ingelheim Investigational Site 535 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lohne : Boehringer Ingelheim Investigational Site 968 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lollar : Boehringer Ingelheim Investigational Site 550 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lu.-Ruchheim : Boehringer Ingelheim Investigational Site 412 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lucka : Boehringer Ingelheim Investigational Site 1188 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luckau : Boehringer Ingelheim Investigational Site 1208 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luckenwalde : Boehringer Ingelheim Investigational Site 1320 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 169 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 153 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 162 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 163 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 138 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : Boehringer Ingelheim Investigational Site 161 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigsburg : 1160.136.02008 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Ludwigshafen : Klinikum der Stadt Ludwigshafen am Rhein gGmbH

Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Ludwigshafen : Boehringer Ingelheim Investigational Site 398 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigshafen : Boehringer Ingelheim Investigational Site 389 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Ludwigslust : Boehringer Ingelheim Investigational Site 1096 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebben : Boehringer Ingelheim Investigational Site 1209 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebeck : Boehringer Ingelheim Investigational Site 1046 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luebeck : Boehringer Ingelheim Investigational Site 1081 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 741 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 721 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 740 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luedenscheid : Boehringer Ingelheim Investigational Site 736 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 1016 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 1012 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lueneburg : Boehringer Ingelheim Investigational Site 1014 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luenen : Boehringer Ingelheim Investigational Site 363 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luetzen : Boehringer Ingelheim Investigational Site 1390 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Luetzow : Boehringer Ingelheim Investigational Site 1105 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lutherstadt Wittenberg : Boehringer Ingelheim Investigational Site 1371 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Lutzerath : Boehringer Ingelheim Investigational Site 421 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Maerkische Heide/ Gross Leuthen : Boehringer Ingelheim Investigational Site 1428 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Maerkische Heide/Gross Leuthen : Boehringer Ingelheim Investigational Site 1219 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1433 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1263 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : Boehringer Ingelheim Investigational Site 1257 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Magdeburg : University Hospital Magdeburg; Div. of Cardiology

Irbesartan and Adhesion Molecules in AF

Mainaschaff : Boehringer Ingelheim Investigational Site 194 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainburg : Boehringer Ingelheim Investigational Site 311 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 465 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 460 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : Boehringer Ingelheim Investigational Site 459 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mainz : 1160.136.02053 Boehringer Ingelheim Investigational Site Updated

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Malterdingen : Boehringer Ingelheim Investigational Site 29 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : University Hospital of Mannheim

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Mannheim : Boehringer Ingelheim Investigational Site 1437 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 112 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 107 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 1440 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 115 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 117 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 106 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim : Boehringer Ingelheim Investigational Site 103 Updated

Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment

Mannheim (Almenhof) : Boehringer Ingelheim Investigational Site 114 Updated

Dabigatran Etexilate for Stroke Prevention in Patie